| Somatic mutations of calreticulin in myeloproliferative neoplasms T Klampfl, H Gisslinger, AS Harutyunyan, H Nivarthi, E Rumi, JD Milosevic, ... New England Journal of Medicine 369 (25), 2379-2390, 2013 | 2381 | 2013 |
| New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment F Cervantes, B Dupriez, A Pereira, F Passamonti, JT Reilly, E Morra, ... Blood, The Journal of the American Society of Hematology 113 (13), 2895-2901, 2009 | 1512 | 2009 |
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and … F Passamonti, F Cervantes, AM Vannucchi, E Morra, E Rumi, A Pereira, ... Blood, The Journal of the American Society of Hematology 115 (9), 1703-1708, 2010 | 1086 | 2010 |
| Cardiovascular events and intensity of treatment in polycythemia vera R Marchioli, G Finazzi, G Specchia, R Cacciola, R Cavazzina, D Cilloni, ... New England Journal of Medicine 368 (1), 22-33, 2013 | 946 | 2013 |
| Mutations and prognosis in primary myelofibrosis AM Vannucchi, TL Lasho, P Guglielmelli, F Biamonte, A Pardanani, ... Leukemia 27 (9), 1861-1869, 2013 | 873 | 2013 |
| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study A Tefferi, E Rumi, G Finazzi, H Gisslinger, AM Vannucchi, F Rodeghiero, ... Leukemia 27 (9), 1874-1881, 2013 | 814 | 2013 |
| JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes E Rumi, D Pietra, V Ferretti, T Klampfl, AS Harutyunyan, JD Milosevic, ... Blood, The Journal of the American Society of Hematology 123 (10), 1544-1551, 2014 | 757 | 2014 |
| Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis) T Barbui, G Finazzi, A Carobbio, J Thiele, F Passamonti, E Rumi, ... Blood, The Journal of the American Society of Hematology 120 (26), 5128-5133, 2012 | 667 | 2012 |
| Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia F Passamonti, E Rumi, E Pungolino, L Malabarba, P Bertazzoni, ... The American journal of medicine 117 (10), 755-761, 2004 | 630 | 2004 |
| Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study T Barbui, J Thiele, F Passamonti, E Rumi, E Boveri, M Ruggeri, ... Journal of clinical oncology 29 (23), 3179-3184, 2011 | 584 | 2011 |
| Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients A Carobbio, J Thiele, F Passamonti, E Rumi, M Ruggeri, F Rodeghiero, ... Blood, The Journal of the American Society of Hematology 117 (22), 5857-5859, 2011 | 518 | 2011 |
| MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis P Guglielmelli, TL Lasho, G Rotunno, M Mudireddy, C Mannarelli, ... Journal of Clinical Oncology 36 (4), 310-318, 2018 | 506 | 2018 |
| Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis E Rumi, D Pietra, C Pascutto, P Guglielmelli, A Martínez-Trillos, I Casetti, ... Blood, The Journal of the American Society of Hematology 124 (7), 1062-1069, 2014 | 483 | 2014 |
| Clinical significance of somatic mutation in unexplained blood cytopenia L Malcovati, A Gallì, E Travaglino, I Ambaglio, E Rizzo, E Molteni, C Elena, ... Blood, The Journal of the American Society of Hematology 129 (25), 3371-3378, 2017 | 466 | 2017 |
| A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and … F Passamonti, E Rumi, D Pietra, C Elena, E Boveri, L Arcaini, E Roncoroni, ... Leukemia 24 (9), 1574-1579, 2010 | 456 | 2010 |
| Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders D Pietra, S Li, A Brisci, F Passamonti, E Rumi, A Theocharides, M Ferrari, ... Blood, The Journal of the American Society of Hematology 111 (3), 1686-1689, 2008 | 417 | 2008 |
| The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients P Guglielmelli, TL Lasho, G Rotunno, J Score, C Mannarelli, A Pancrazzi, ... Leukemia 28 (9), 1804-1810, 2014 | 345 | 2014 |
| Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations F Passamonti, C Elena, S Schnittger, RC Skoda, AR Green, F Girodon, ... Blood, The Journal of the American Society of Hematology 117 (10), 2813-2816, 2011 | 331 | 2011 |
| Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative … F Passamonti, E Rumi, D Pietra, MGD Porta, E Boveri, C Pascutto, ... Blood 107 (9), 3676-3682, 2006 | 331 | 2006 |
| A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on … F Passamonti, J Thiele, F Girodon, E Rumi, A Carobbio, H Gisslinger, ... Blood, The Journal of the American Society of Hematology 120 (6), 1197-1201, 2012 | 327 | 2012 |
